Retevmo (selpercatinib) — Medica
Non-small cell lung cancer, recurrent, advanced, or metastatic, RET fusion-positive
Initial criteria
- Patient is age ≥ 18 years
- Patient has recurrent, advanced, or metastatic non-small cell lung cancer
- Tumor is rearranged during transfection (RET) fusion-positive
Approval duration
1 year